News
Market and company headlines
DGXAll
Loading
13:00-20:00Oct 232 Stories
Quest Diagnostics (DGX) Backs At Home Cervical Cancer Screening
Quest Diagnostics (NYSE:DGX) and Waters Corporation announced a collaboration to expand access to the Onclarity Self-Collection Kit for cervical cancer screening. The partnership focuses on at-home sample collection that can be processed through Quest Diagnostics laboratories using the Onclarity HPV assay. The two companies aim to widen access to clinically appropriate cervical cancer testing for patients who face barriers to in clinic screening. The Onclarity Self-Collection Kit...
Quest Diagnostics (DGX) Stock Could Be Undervalued Despite Raised Full Year Guidance
Quest Diagnostics has delivered a strong share price run in recent years, and fresh headlines about product expansion and digital health tie-ups keep interest high. With the stock now reflecting years of gains, the open question is whether the business's cash flows are enough to justify where the valuation sits today. Over the past 3 years, Quest Diagnostics has returned 96.2%, which puts a lot of focus on whether its cash generation can continue to support that kind of share price...
11:00Oct 231 Story
14:00Oct 222 Stories
Quest Diagnostics: 3 Key Takeaways for Long-Term Investors
Automation and direct-to-consumer expansion are offsetting wage inflation and Medicare reimbursement pressure, the dual challenge facing diagnostics providers.
What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call
Quest Diagnostics (NYSE:DGX) reported third-quarter 2026 revenue growth of 10% and adjusted earnings-per-share growth of more than 15%, citing demand across its physician, hospital and consumer channels as well as productivity gains from automation and artificial intelligence. The company raised and
13:00Oct 223 Stories
Quest Diagnostics (DGX) Q3 2026 Earnings Call Transcript
Revenue grew 10% as automation and AI boosted margins amid regulatory headwinds.
Quest Diagnostics Incorporated Q3 2026 Earnings Call Summary
Moby summary of Quest Diagnostics Incorporated's Q3 2026 earnings call
DGX Q3 Earnings & Revenues Beat, '26 View Raised, Stock Down in Pre-Market
09:00Oct 222 Stories
07:00Oct 221 Story
12:00Oct 211 Story
09:00Oct 201 Story
07:00Oct 191 Story
08:00Oct 141 Story
18:00Oct 121 Story
08:00Oct 91 Story
07:00Oct 72 Stories
Natera: Priced To Perfection Amidst Rising Competitive Threats
Natera is rated Sell, as its valuation is stretched, with perfect execution priced in, despite looming competitive threats. Click to read more about NTRA.
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $250 to $260.
07:00Oct 51 Story
07:00Sep 251 Story
04:00-14:00Sep 232 Stories
Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch
Quest Diagnostics (DGX) drew fresh attention after announcing an Apple Health integration that allows iPhone and iPad users to order a preventive lab panel with more than 50 biomarkers for US$119. The Apple Health tie-in lands after a strong run in Quest Diagnostics’ shares, with the price up 15.6% over 90 days and 35.1% year to date, even though the last month’s share price return slipped 3.9% as traders reassessed shorter term risk and reward. Scan beyond Quest Diagnostics and see how other...
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds
Quest Diagnostics outlook: recurring testing demand & acquisitions support growth via hospital partnerships, dialysis & advanced diagnostics. More on DGX stock.
16:00-18:00Sep 222 Stories
Quest Diagnostics (DGX) Stock Could Be 30% Below Fair Value Following Medicare Payment Cut Concerns
Quest Diagnostics has delivered a strong run in recent years, which raises a straightforward question for investors who care about fundamentals. Is the current share price still aligned with the cash the business is expected to generate over time, or has sentiment moved ahead of its underlying economics? Over the past 3 years, Quest Diagnostics has returned 108.9%, which puts real weight on whether that gain is grounded in durable cash flows rather than just multiple expansion. A recent...
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
10:00-12:00Sep 222 Stories
Why Quest Diagnostics Holdings Stock Dropped Today
The government thinks it's been overpaying Quest Diagnostics. They plan to stop doing that next year.
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.
08:00Sep 221 Story
08:00-11:00Sep 212 Stories
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
Quest Diagnostics (NYSE:DGX) CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions. D
Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
Nearly one in three patients found to have antibodies against the bacterium that causes Lyme disease also had antibodies against one or more additional tick-borne pathogens, according to a new study by researchers from Quest Diagnostics (NYSE: DGX) and the University of North Carolina at Chapel Hill.
04:00-06:00Sep 212 Stories
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $250 to $260.
Quest Diagnostics Study Indicates That Nearly One In Three Patients With Antibodies Against Bacterium That Causes Lyme Disease Also Had Antibodies Against One Or More Additional Tick-Borne Pathogens
New study by researchers from Quest Diagnostics (NYSE:DGX) and the University of North Carolina at Chapel Hill. Published in JAMA Network Open, the study, titled "Coseropositivity to Tick-Borne Pathogens Among
08:00Sep 171 Story
08:00-10:00Sep 162 Stories
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
A new national survey finds the overwhelming majority of American voters rely on diagnostic laboratory testing to guide their healthcare decisions and are deeply concerned about scheduled Medicare payment cuts that could put that access at risk.
10:00Sep 151 Story
09:00Sep 141 Story
16:00Sep 91 Story
10:00-13:00Aug 212 Stories
Is it the Right Time to Retain DGX Stock in Your Portfolio?
Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
03:00Aug 201 Story
21:00Aug 191 Story
10:00-14:00Aug 182 Stories
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WHOOP Makes Advanced Labs Available Without a Wearable Membership
BOSTON, August 18, 2026--WHOOP, the human performance brand, today announced it is expanding access to proactive health, adding Galleri®, GRAIL's multi-cancer early detection test and, for the first time, making WHOOP Advanced Labs available without a membership. WHOOP Advanced Labs is powered in the U.S. by Quest Diagnostics (NYSE: DGX).
04:00Aug 181 Story
09:00Aug 132 Stories
National Vision Stock Down Despite Q2 Earnings & Revenue Beat
EYE beats Q2 earnings and revenue estimates, expands operating margin and raises its 2026 profit outlook despite gross margin pressure.
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.
16:00Aug 121 Story
09:00-14:00Aug 112 Stories
Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down
HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.
Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs
ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.
09:00-11:00Aug 102 Stories
Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?
LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.
PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down
Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.
